Chua et al. Clin Lung Cancer 2014
Kouroussis et al. Oncology 2009
WBRT + Temozolomide
WBRT +/- temozolomide
:
• Patients with NSCLC and > 1 newly
diagnosed brain metastasis
• Poor accrual
• WBRT alone: median OS: 5.7 months
• WBRT + temozolomide: median OS 4.4
Daily low-dose temozolomide:
• Patients with advanced NSCLC; many of them
with brain mets
• “minimal activity as salvage therapy in patients
with advanced NSCLC”